Engineered nanoparticle platforms have been developed intensely in recent years, yielding significantly broadened applications from interrogating novel biology to new therapies. Using these platforms requires improved understanding of design rules to improve our ability to control nanoparticle-immune system interactions.
No takes yet. Share an insight, caveat, or question.
Szeto et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: